CClinicalTrials.gg
CompletedNCT03504124Updated Jul 29, 2022

Multicomponent Intervention to Improve Hypertension Control in Central America

A Phase 3 interventional study of Multicomponent intervention in Arterial Hypertension, sponsored by Institute of Nutrition of Central America and Panama. Completed at 1 site in Guatemala. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-07-29.

Sponsored by Institute of Nutrition of Central America and Panama · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
1,854
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The investigators propose to assess the needs, barriers, and knowledge gaps of hypertension control programs in the national health care systems of the Central America 4 region LMIC (CA-4: Guatemala, Honduras, El Salvador, and Nicaragua); to conduct a cluster randomized trial to test the effect of a multilevel and multicomponent intervention program leveraging an existing subnational primary healthcare system in Guatemala, on blood pressure (BP) control among hypertensive patients; and to evaluate the adaptability, feasibility, fidelity, and sustainability of implementing the program in the primary health care systems of the CA-4 region. The comprehensive intervention, which includes protocol-based treatment using a standard BP management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification, will last for 18 months. This implementation research study presents high public health impact because it will generate urgently needed data on effective, practical, and sustainable intervention strategies aimed at reducing BP related disease burden in Central America and other low- and middle-income countries.

Read the detailed description

Despite advances in hypertension prevention and treatment research, its prevalence is high and increasing, while the proportions of hypertensive patients who are aware, treated, and controlled are low, especially in low- and middle-income countries (LMIC). The investigators propose to: assess the needs, barriers, and knowledge gaps of hypertension control programs in the national health care systems of the Central America 4 region LMIC (CA-4: Guatemala, Honduras, El Salvador, and Nicaragua); conduct a cluster randomized trial to test the effect of a multilevel and multicomponent intervention program on blood pressure (BP) control among Guatemalan hypertensive patients; and evaluate the adaptability, feasibility, fidelity, and sustainability of implementing the program in the primary health care systems of the CA-4 region. The investigators will conduct formative research to assess the needs of system-wide intervention programs, barriers and facilitators of BP control strategies, and knowledge gaps about implementation for improving hypertension control in the CA-4 health care systems. The proposed trial will recruit 1,770 study participants from 32 primary care districts (55 patients aged ≥22 years with uncontrolled hypertension/district) within a subnational primary care network managed by the Guatemalan Ministry of Health. Sixteen health districts will be assigned to an 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification, and 16 to usual care. BP and other indicators will be measured at baseline and at months 6, 12, and 18. The primary clinical outcome is the difference in the proportion of patients with controlled BP (\<140/90 mmHg) between the intervention and control groups at 18 months. The secondary outcome is net change in systolic and diastolic BP from baseline to 18 months. Fidelity of the intervention measured monthly by intensification of treatment by provider-teams (titration or addition of new medications) and adherence to medications in patients will be the primary implementation outcome. Other implementation outcomes will be measured every 6 months. The RE-AIM framework will guide the development, implementation, and assessment of the intervention, which will translate and adapt the Hypertension Control Program in Argentina that has been proven effective and feasible. This project have assembled a multidisciplinary investigative team, which will collaborate with the public primary care network in Guatemala to conduct this implementation research project. The intervention and study outcomes are patient-centered, and patients, MOH provider-teams, and other stakeholders will be engaged at every step of the proposed study. The investigators will disseminate the study findings and promote scale-up of the proven effective intervention program, which will generate urgently needed data on effective, adoptable, and sustainable intervention strategies aimed at reducing BP-related disease burden in CA-4 and other low-income settings.

02

Conditions studied

  • Arterial Hypertension

Browse trials for

03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 1,854 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Institute of Nutrition of Central America and Panama is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All patients aged ≥40 years with BP >140/90 mmHg at the time of enrollment
  • Patients who receive care at government health facilities

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,854 participants (actual)

Study arms

  • Experimental
    Intervention group

    Patients will receive a multicomponent intervention.

    Other: Multicomponent intervention

  • No intervention
    Control group

    Patients will receive the usual care.

Interventions

  • OtherMulticomponent intervention

    An 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.

06

What researchers measure

Primary outcomes

  1. Proportion of controlled blood pressure

    Difference in the proportion of patients with controlled blood pressure (\<140/90 mmHg) between the intervention and control groups

    Time frame: 18 months

Secondary outcomes

  1. Change in systolic blood pressure

    Net change in systolic blood pressure from baseline to 18 months

    Time frame: 18 months

  2. Change in diastolic blood pressure

    Net change in diastolic blood pressure from baseline to 18 months

    Time frame: 18 months

07

Study locations

1 site
  • Insitute of Nutrition of Central America and Panama
    Guatemala, 01011, Guatemala
08

References and documents

Publications

  • Paniagua-Avila A, Fort MP, Glasgow RE, Gulayin P, Hernandez-Galdamez D, Mansilla K, Palacios E, Peralta AL, Roche D, Rubinstein A, He J, Ramirez-Zea M, Irazola V. Evaluating a multicomponent program to improve hypertension control in Guatemala: study protocol for an effectiveness-implementation cluster randomized trial. Trials. 2020 Jun 9;21(1):509. doi: 10.1186/s13063-020-04345-8. PubMed 32517806 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03504124
Lead sponsor
Institute of Nutrition of Central America and Panama
Collaborators
Tulane University School of Public Health and Tropical Medicine, Institute for Clinical Effectiveness and Health Policy, Colorado School of Public Health, National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Manuel Ramirez-Zea (Head, INCAP Research Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central America and Panama) — Principal investigator
First posted
Apr 20, 2018
Start date
Jul 17, 2019
Primary completion
Apr 23, 2022
Completion
Apr 23, 2022
Last update
Jul 29, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion